chemotherapy

envie a um amigo share this

A new study reveals that the RNA‑binding protein YTHDF3 affects gastric cancer cell migration and response to paclitaxel by regulating EZRIN

Researchers from the "Differentiation and Cancer" group at i3S, in collaboration with “Cancer Metastasis” and “Cell Division & Genomic Stability” groups and Carmen Jerónimo from IPO-Porto, elucidated the role of YTHDF3, a key m6A RNA “reader” protein, as a driver of gastric cancer (GC) progression and paclitaxel sensitivity. This new study, entitled "The RNA‑binding protein YTHDF3 affects gastric cancer cell migration and response to paclitaxel by regulating EZRIN," was recently published in the journal "Gastric Cancer”.

Estudo pré-clínico com Avatares de cancro de mama prevê resposta à quimioterapia

Autores e Afiliações:

Raquel V Mendes 1, Joana M Ribeiro # 2, Helena Gouveia # 3, Cátia Rebelo de Almeida 1, Mireia Castillo-Martin 1 4, Maria José Brito 4, Rita Canas-Marques 4, Eva Batista 3, Celeste Alves 3, Berta Sousa 3, Pedro Gouveia 3, Miguel Godinho Ferreira 5, Maria João Cardoso 3 6, Fatima Cardoso 3, Rita Fior 7

Zebrafish Avatar testing preclinical study predicts chemotherapy response in breast cancer

Authors and Affiliations:

Raquel V Mendes 1, Joana M Ribeiro # 2, Helena Gouveia # 3, Cátia Rebelo de Almeida 1, Mireia Castillo-Martin 1 4, Maria José Brito 4, Rita Canas-Marques 4, Eva Batista 3, Celeste Alves 3, Berta Sousa 3, Pedro Gouveia 3, Miguel Godinho Ferreira 5, Maria João Cardoso 3 6, Fatima Cardoso 3, Rita Fior 7

Combination of gene therapy and chemotherapy in a new targeted hybrid nanosystem to hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is one of the main causes of cancer death worldwide. Thus, the main objective of this work was to develop a new targeted lipid-polymer hybrid nanosystem that could allow the simultaneous transport of different therapeutic agents, namely antitumor drugs and nucleic acids, and their specific delivery in HCC cells. This formulation has the capability to mediate combined chemotherapy and gene therapy, as it efficiently loaded and delivered, in target cells, the drugs selumetinib and perifosine, and the PTEN transgene.

Disruption of breast cancer cell pH dynamics decreases aggressiveness and potentiates response to chemotherapy

The reverse pH gradient is a common feature of cancer cells, in which the intracellular pH is more alkaline and the extracellular more acidic. This phenotype is supported by increased activity of pH regulators like ATPases, carbonic anhydrases (CAs), monocarboxylate transporters (MCTs) and sodium–proton exchangers (NHEs). In this work, we analyzed the expression of these pH regulators and explored their inhibition in breast cancer cells as a therapeutic strategy.

Patient-derived ovarian cancer explants: preserved viability and histopathologic

Ovarian carcinoma remains a major therapeutic challenge due to its tendency to develop resistance after initial response to chemotherapy. In this work, a collaboration between iBET, AbbVie and IPOLFG, we developed ovarian carcinoma patient-derived explant (OvC-PDE) cultures that retained architecture and cell type heterogeneity of the original tumour. This patient-derived model have potential applications in the study of drug response and resistance mechanisms and in the development of innovative precision medicine approaches.

Patient-derived ovarian cancer explants: preserved viability and histopathologic

Ovarian carcinoma remains a major therapeutic challenge due to its tendency to develop resistance after initial response to chemotherapy. In this work, a collaboration between iBET, AbbVie and IPOLFG, we developed ovarian carcinoma patient-derived explant (OvC-PDE) cultures that retained architecture and cell type heterogeneity of the original tumour. This patient-derived model have potential applications in the study of drug response and resistance mechanisms and in the development of innovative precision medicine approaches.

MiR-144 overexpression as a promising therapeutic strategy to overcome glioblastoma cell invasiveness and resistance to chemotherapy

Authors and Affiliations:

Cardoso AMS1,2, Sousa M1,3, Morais CM1,3, Oancea-Castillo LR4, Régnier-Vigouroux A4, Rebelo O5, Tão H6, Barbosa M6,7, Pedroso de Lima MC1, Jurado AS1,3.

1 Center for Neuroscience and Cell Biology, University of Coimbra, 3004-504 Coimbra, Portugal.

2 Institute for Interdisciplinary Research of the University of Coimbra, 3030-789 Coimbra, Portugal.

New mechanism behind Doxorubicin cardiotoxicity

A group of researchers from the Center for Neuroscience and Cell Biology (CNC) at the University of Coimbra (UC), uncovered a new mechanism behind the cardiotoxicity of the anticancer drug Doxorubicin (or Adriamycin) that can be explored in the future as a new therapeutic target to counteract the adverse effects of chemotherapy. Although Doxorubicin is a powerful chemotherapeutic agent, it has severe long-term adverse effects that compromise the cardiac function of patients.

Findings reveal a mitochondrial metabolic vulnerability that might be exploited to kill chemotherapy-resistant acute myeloid leukemia cells

Authors and Affiliations:

Sandrina Nóbrega-Pereira1, Francisco Caiado1, Tânia Carvalho1, Inês Matias1, Gonçalo Graça2, Luís Gafeira Gonçalves2, Bruno Silva-Santos1, Haakan Norell1 and Sérgio Dias1

1 Instituto de Medicina Molecular.
  • 2 Instituto de Tecnologia Quimica e Biológica.

 

Abstract: